HC Wainwright Reiterates “Buy” Rating for Aeterna Zentaris Inc. (AEZS)
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report released on Sunday. They currently have a $12.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 242.86% from the company’s previous close.
Other equities analysts also recently issued research reports about the stock. Canaccord Genuity reiterated a “buy” rating and issued a $9.00 price target on shares of Aeterna Zentaris in a report on Tuesday, August 23rd. Zacks Investment Research upgraded shares of Aeterna Zentaris from a “hold” rating to a “buy” rating and set a $4.00 price target for the company in a report on Monday, August 15th. Finally, Maxim Group reiterated a “buy” rating and issued a $11.00 price target on shares of Aeterna Zentaris in a report on Saturday, August 13th.
Aeterna Zentaris (NASDAQ:AEZS) opened at 3.50 on Friday. The firm’s market capitalization is $34.79 million. Aeterna Zentaris has a 12-month low of $2.60 and a 12-month high of $15.70. The firm has a 50-day moving average of $3.79 and a 200 day moving average of $3.56.
About Aeterna Zentaris
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Receive News & Stock Ratings for Aeterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris Inc. and related stocks with our FREE daily email newsletter.